The acquisition will cost around $2 billion at $21 per share, with an additional $400 million to be paid to Fusion if the biotech firm satisfies specific requirements.
This move is part of AstraZeneca’s cancer treatment pipeline expansion, as Fusion is focused on next-generation radioconjugates that kill cancer cells more accurately than chemotherapy, reducing risk for healthy cells.
